Molecular therapy for Cardiomyopathy: A pharmaceutical mixture (PMSFN) encompassing  Pyridoxamin (PM) and Sulphoraphane (SFN) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 17/December/2017,  11.03 pm

Amino acid-based therapy for ageing-associated diseases and Lifespan extension: D-Serine increases NMN/NAD levels, decreases interaction of DBC1 with PARP1, increases PARP1 activity, promotes DNA repair, augments tolerance against radiation, cancer and aging via down regulation of its target gene, 17/December/2017, 10.52 pm
December 17, 2017
Natural product therapy for pulmonary arterial hypertension: Glycyrrhetinic acid, isolated from Licorice, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 17/December/2017, 11.42 pm
December 17, 2017
Show all

Introduction: What they say  

A study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that Trbp regulates heart function through microRNA-mediated Sox6 repression.” This study was published, in the 2 June  2015 issue of the journal “Nature Genetics” (the number 1 research journal in Genetics with an impact factor of 29.648), by Prof. Da-Zhi Wang & Jian Ding, and others


What we say:

On the foundation of these interesting findings, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Cardiomyopathy: A pharmaceutical mixture (PMSFN) encompassing  Pyridoxamin (PM) and Sulphoraphane (SFN) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene


From significance of the study to public health relevance:

Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) dilated cardiomyopathy is the leading cause of Heart failure; (3) the raise  of death rate, due to cardiovascular disease, has increased from 12.3 million in 1990 to 17.3 million in 2013; (4) 13% of cardiovascular disease occur due to  uncontrolled high blood pressure; (5) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (6) 85% of people over  80 years are susceptible to cardiovascular diseases; (7) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (8) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; and (9) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find:  (i) a cure to diseases, as mentioned above, leading to cardiovascular disease; (ii) a way to induce regeneration of adult cardiomyocytes that were lost in Myocardial patients; (iii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


What is known?

A number of studies suggests that Cardiomyopathy is the result of altered gene expression of contractile proteins. Trbp, an RNA binding protein, has been shown to be required for normal functioning of heart contractions.

Prof Da-Zhi Wang’s research team has shown earlier that inactivation of Trbp in mice leads to progressive cardiomyopathy and heart failure. 


From research findings to Therapeutic opportunity: 

This study suggests  a combinatorial therapy for Cardiomyopathy.  A pharmaceutical mixture (PMSFN) encompassing  Pyridoxamin (PM) and Sulphoraphane (SFN), by regulating  the expression of its target genes, it may: (1) decrease the expression of Sox6; (2) increase the expression of cardiac slow-twitch myofiber proteins; (3) decrease the expression of skeletal fast-twitch myofiber proteins (4) restore the balance between slow- and fast-twitch myofiber proteins; and (5) alleviate cardiomyopathy (fig. 1).

Figure 1. Mechanistic insights into how a pharmaceutical mixture (PMSFN) encompassing  Pyridoxamin (PM) and Sulphoraphane (SFN) functions as a cardioprotective agent. PMSFN, by increasing the expression of its target genes, it may decrease the expression of Sox6. Thereby, it may increase cardiomyocyte proliferation, augment the number of beating cardiomyocytes, and attenuate cardiomyopathy.

Figure 2. The chemical structures of Pyridoxamine (PM) and Sulforaphane (SFN).

Thus, pharmacological formulations encompassing Pyridoxamin (PM) and Sulphoraphane (SFN) or their analogues, either alone or in combination with other drugs” may be used to inhibit progressive cardiomyopathy and lethal heart failure.

[easy_payment currency=”USD”]


Details of the research findings:

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How a pharmaceutical mixture (PMSFN) encompassing  Pyridoxamin (PM) and Sulphoraphane (SFN) inhibits the expression of Sox6.

#Research cooperation

Amount: $500#

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org

To citeBoominathan, L., Molecular therapy for Cardiomyopathy: A pharmaceutical mixture (PMSFN) encompassing  Pyridoxamin (PM) and Sulphoraphane (SFN) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 17/December/2017,  11.03 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

 

Comments are closed.